Skip to main content
. 2018 Jan 26;19:20. doi: 10.1186/s12931-018-0717-z

Table 2.

Univariate associations of thrombocytosis (platelet count ≥350 × 109/L) with COPD morbidity

Outcomes [% or mean ± standard deviation] SPIROMICS COPDGene
Platelet Count <350 × 109/L Platelet Count ≥350 × 109/L p-value Platelet Count <350 × 109/L Platelet Count ≥350 × 109/L p-value
Any Acute Exacerbation of COPD during the prior year 30.7% 43.6% 0.003* 27.5% 37.8% 0.02*
Severe Acute Exacerbation of COPD during the prior year 15.5% 24.2% 0.01* 14.6% 23.4% 0.01*
Modified Medical Research Council (mMRC) Questionnaire score ≥ 2 31.4% 47.5% 0.0002* 52.9% 64% 0.02*
COPD Assessment Test (CAT) score ≥ 10 72.4% 86.2% 0.001* 66.4% 77.5% 0.02*
GOLD symptom group D 20% 33% 0.0009* 19.4% 33.3% 0.0004*
6-min walk distance in meters 395 ± 128 352 ± 134 0.007a 371 ± 124 358 ± 118 0.3a
St. George Respiratory Questionnaire score 38 ± 20 44 ± 19 0.0002a 32 ± 22 38 ± 24 0.005a

GOLD Global Initiative for Chronic Obstructive Lung Disease. *chi-squared test; at-test